HUE045220T2 - Imidazopiridazin-származékok mint PI3Kbéta inhibitorok - Google Patents
Imidazopiridazin-származékok mint PI3Kbéta inhibitorokInfo
- Publication number
- HUE045220T2 HUE045220T2 HUE15810784A HUE15810784A HUE045220T2 HU E045220 T2 HUE045220 T2 HU E045220T2 HU E15810784 A HUE15810784 A HU E15810784A HU E15810784 A HUE15810784 A HU E15810784A HU E045220 T2 HUE045220 T2 HU E045220T2
- Authority
- HU
- Hungary
- Prior art keywords
- pi3kbeta
- inhibitors
- imidazopyridazine derivatives
- imidazopyridazine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14199322 | 2014-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE045220T2 true HUE045220T2 (hu) | 2019-12-30 |
Family
ID=52134002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15810784A HUE045220T2 (hu) | 2014-12-19 | 2015-12-18 | Imidazopiridazin-származékok mint PI3Kbéta inhibitorok |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10087187B2 (hu) |
| EP (1) | EP3233862B1 (hu) |
| JP (1) | JP6568588B2 (hu) |
| KR (1) | KR20170095239A (hu) |
| CN (1) | CN107108634B (hu) |
| AU (1) | AU2015366190B2 (hu) |
| BR (1) | BR112017012930A2 (hu) |
| CA (1) | CA2967551A1 (hu) |
| CY (1) | CY1122381T1 (hu) |
| DK (1) | DK3233862T3 (hu) |
| EA (1) | EA029789B1 (hu) |
| ES (1) | ES2761051T3 (hu) |
| HR (1) | HRP20191550T1 (hu) |
| HU (1) | HUE045220T2 (hu) |
| IL (1) | IL252866B (hu) |
| LT (1) | LT3233862T (hu) |
| MA (1) | MA41174B1 (hu) |
| MD (1) | MD3233862T2 (hu) |
| ME (1) | ME03517B (hu) |
| MX (1) | MX2017008074A (hu) |
| PL (1) | PL3233862T3 (hu) |
| PT (1) | PT3233862T (hu) |
| RS (1) | RS59301B1 (hu) |
| SI (1) | SI3233862T1 (hu) |
| WO (1) | WO2016097347A1 (hu) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10526316B2 (en) | 2015-10-09 | 2020-01-07 | Janssen Pharmaceutica Nv | Quinoxaline and pyridopyrazine derivatives as PI3Kβ inhibitors |
| KR102472453B1 (ko) | 2016-06-16 | 2022-11-29 | 얀센 파마슈티카 엔.브이. | Pi3k 베타 저해제로서의 이환식 피리딘, 피라진, 및 피리미딘 유도체 |
| BR112019020309A2 (pt) | 2017-03-29 | 2020-04-28 | Janssen Pharmaceutica Nv | derivados de quinoxalina e piridopirazina como inibidores de pi3k-beta |
| CN110128505A (zh) * | 2019-05-21 | 2019-08-16 | 梯尔希（南京）药物研发有限公司 | 一种戈舍瑞林杂质的合成方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| US20090215818A1 (en) | 2006-07-24 | 2009-08-27 | Smithkline Beecham Corporation | Thiozolidinedione derivatives as pi3 kinase inhibitors |
| CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| PE20090215A1 (es) * | 2007-05-09 | 2009-03-30 | Novartis Ag | Compuestos derivados de imidazopiridazinas como inhibidores de cinasa |
| EP2217601A1 (en) | 2007-11-08 | 2010-08-18 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyridazines for use as protein kinase inhibitors |
| BRPI0908504A2 (pt) * | 2008-02-28 | 2015-08-11 | Novatis Ag | Compostos derivados de 3-metil-imidazo[1,2-b]piridazina, uso dos mesmos e composição farmacêutica |
| WO2010007099A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Limited | 2-aminoimidazo[1,2-b]pyridazine derivatives as pi3k inhibitors |
| JP5819831B2 (ja) | 2009-08-17 | 2015-11-24 | インテリカイン， エルエルシー | 複素環式化合物およびそれらの使用 |
| DE102009049679A1 (de) * | 2009-10-19 | 2011-04-21 | Merck Patent Gmbh | Pyrazolopyrimidinderivate |
| WO2011058109A1 (en) | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors |
| UY33304A (es) | 2010-04-02 | 2011-10-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| WO2012047538A1 (en) * | 2010-10-06 | 2012-04-12 | Glaxosmithkline Llc | Benzimidazole derivatives as pi3 kinase inhibitors |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| WO2013028263A1 (en) * | 2011-08-24 | 2013-02-28 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as pi3 kinase inhibitors |
| WO2013095761A1 (en) | 2011-12-20 | 2013-06-27 | Glaxosmithkline Llc | Imidazopyridine derivatives as pi3 kinase inhibitors |
| US8778937B2 (en) | 2011-12-20 | 2014-07-15 | Glaxosmithkline Llc | Benzimidazole boronic acid derivatives as PI3 kinase inhibitors |
| TWI574962B (zh) * | 2012-11-14 | 2017-03-21 | 加拓科學公司 | 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途 |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
-
2015
- 2015-12-18 MD MDE20170191 patent/MD3233862T2/ro unknown
- 2015-12-18 CN CN201580069133.7A patent/CN107108634B/zh not_active Expired - Fee Related
- 2015-12-18 PL PL15810784T patent/PL3233862T3/pl unknown
- 2015-12-18 WO PCT/EP2015/080604 patent/WO2016097347A1/en active Application Filing
- 2015-12-18 BR BR112017012930A patent/BR112017012930A2/pt active Search and Examination
- 2015-12-18 JP JP2017532819A patent/JP6568588B2/ja not_active Expired - Fee Related
- 2015-12-18 DK DK15810784.7T patent/DK3233862T3/da active
- 2015-12-18 PT PT158107847T patent/PT3233862T/pt unknown
- 2015-12-18 MA MA41174A patent/MA41174B1/fr unknown
- 2015-12-18 CA CA2967551A patent/CA2967551A1/en active Pending
- 2015-12-18 AU AU2015366190A patent/AU2015366190B2/en not_active Ceased
- 2015-12-18 KR KR1020177016722A patent/KR20170095239A/ko not_active Application Discontinuation
- 2015-12-18 HU HUE15810784A patent/HUE045220T2/hu unknown
- 2015-12-18 SI SI201530855T patent/SI3233862T1/sl unknown
- 2015-12-18 US US15/537,551 patent/US10087187B2/en active Active
- 2015-12-18 EA EA201791396A patent/EA029789B1/ru not_active IP Right Cessation
- 2015-12-18 RS RSP20191225 patent/RS59301B1/sr unknown
- 2015-12-18 ME MEP-2019-263A patent/ME03517B/me unknown
- 2015-12-18 ES ES15810784T patent/ES2761051T3/es active Active
- 2015-12-18 LT LTEP15810784.7T patent/LT3233862T/lt unknown
- 2015-12-18 MX MX2017008074A patent/MX2017008074A/es active IP Right Grant
- 2015-12-18 EP EP15810784.7A patent/EP3233862B1/en active Active
-
2017
- 2017-06-13 IL IL252866A patent/IL252866B/en active IP Right Grant
-
2019
- 2019-08-28 HR HRP20191550 patent/HRP20191550T1/hr unknown
- 2019-10-03 CY CY20191101031T patent/CY1122381T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016097347A1 (en) | 2016-06-23 |
| US20180002336A1 (en) | 2018-01-04 |
| CN107108634B (zh) | 2020-09-15 |
| HRP20191550T1 (hr) | 2019-11-29 |
| DK3233862T3 (da) | 2019-10-07 |
| ES2761051T3 (es) | 2020-05-18 |
| KR20170095239A (ko) | 2017-08-22 |
| ME03517B (me) | 2020-04-20 |
| EP3233862B1 (en) | 2019-07-03 |
| CY1122381T1 (el) | 2021-01-27 |
| IL252866A0 (en) | 2017-08-31 |
| AU2015366190B2 (en) | 2020-01-23 |
| US10087187B2 (en) | 2018-10-02 |
| PT3233862T (pt) | 2019-10-09 |
| MA41174B1 (fr) | 2019-09-30 |
| JP2017538734A (ja) | 2017-12-28 |
| EP3233862A1 (en) | 2017-10-25 |
| MX2017008074A (es) | 2018-01-09 |
| LT3233862T (lt) | 2019-09-10 |
| BR112017012930A2 (pt) | 2018-01-09 |
| PL3233862T3 (pl) | 2020-01-31 |
| MD3233862T2 (ro) | 2019-11-30 |
| EA029789B1 (ru) | 2018-05-31 |
| RS59301B1 (sr) | 2019-10-31 |
| CA2967551A1 (en) | 2016-06-23 |
| JP6568588B2 (ja) | 2019-08-28 |
| CN107108634A (zh) | 2017-08-29 |
| IL252866B (en) | 2020-09-30 |
| EA201791396A1 (ru) | 2017-10-31 |
| MA41174A (fr) | 2017-10-25 |
| SI3233862T1 (sl) | 2019-09-30 |
| AU2015366190A1 (en) | 2017-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL287113A (en) | smyd inhibitors | |
| IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
| IL251420A0 (en) | Triazolopyrazinones as pde1 inhibitors | |
| HK1226398A1 (zh) | 作為midh1抑制劑的苯並咪唑-2-胺 | |
| IL251932B (en) | Benzylpropargyl ether as nitrification inhibitors | |
| SG11201610904UA (en) | Syk inhibitors | |
| IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
| PL3131898T3 (pl) | Pochodne fluoroalkilofluorenu | |
| IL248629B (en) | Substances containing diheteroaryl conjugated to cycloalkyl and their uses | |
| IL252866B (en) | History of imidazopyridazine as pi3k beta inhibitors | |
| PL3418273T3 (pl) | Pochodne flawaglin | |
| AP2016009545A0 (en) | Naphthyridinedione derivatives | |
| IL252868A0 (en) | History of heterocyclyl-related imidazopyridazines as pi3kbeta inhibitors | |
| HK1232214A1 (zh) | 作為 抑制劑的六氫呋喃並吡咯 | |
| PL3119744T3 (pl) | Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu | |
| GB201418154D0 (en) | Inhibitors |